FXi-related ICH cases included traumatic and spontaneous intracranial hemorrhages.
We conducted a retrospective review of consecutive adult patients with FXi-related ICH who received AA or 4F-PCC. We sought to describe our experience with AA or 4F-PCC in patients with oral FXi-related traumatic and spontaneous ICH. There are limited data on the risks and benefits of using andexanet alfa (AA) in comparison with four-factor prothrombin complex concentrate (4F-PCC) to reverse factor Xa inhibitors (FXi) associated intracranial hemorrhage (ICH).
0 kommentar(er)
